VIPR1 polyclonal antibody

The vasoactive intestinal peptide (VIP) and pituitary adenylate cylase-activating polypeptide (PACAP) belong to a superfamily of peptide hormones that include glucagon, secretin and growth hormone releasing hormone (1,2) . The effects of VIP and PACAP are mediated by three G-protein coupled receptors, VPAC1, VPAC2 and the PACAP receptor (also designated PAC1-R) (1,2) . The VPAC receptors have equal affinities for VIP and PACAP, which stimulate the activation of adenylyl cyclase (1,3) . Both VPAC1 and VPAC2 are abundantly expressed in brain and T cells, where they modulate neuronal differentiation and T cell activation, respectively (1,4-6) . The PACAP receptor is a seven transmembrane protein that produces at least eight isoforms by alternative splicing (2) . Each isoform is associated with a specific signaling pathway and a specific expression pattern (2) . The PACAP receptor, which is thought to play an integral role in brain development, preferentially binds PACAP in order to stimulate a cAMP-protein kinase A signaling pathway (2,7) .

Vasoactive intestinal polypeptide receptor 1; VIP-R-1; Pituitary adenylate cyclase-activating polypeptide type II receptor; PACAP type II receptor; PACAP-R-2; PACAP-R2; VPAC1; VIPR1

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Western blot (WB) analysis of VIPR1 polyclonal antibody at 1:500 dilution Lane1:A549 whole cell lysate Lane2:H9C2 whole cell lysate Lane3:Raw264.7 whole cell lysate